KLEPTOSE® HPB-LB

Natural pregelatinized starch LYCATAB® PGS: solid dosage forms. This excipient is used as a binder for wet granulation.

Roquette’s LYCOAT® range is a major breakthrough in aqueous film coating and film forming.

Native starches of plant origins : Maize, wheat and potato. Extra white maize starch has a disintegration function and can be used as insoluble diluents.

Delivering secure supply with the right partner. Trust is the most essential ingredient.

Coprocessed MCC and CMC. An efficient suspending agent.

White to yellow powders food ingredient obtained from maize tapioca and potato starch by heat treatment. Ingredients for clinical nutrition & nutraceuticals.

Precision Dispense helps you streamline complex Biopharmaceutical workflows to bring valuable drug products to market quickly and safely.

Discover how we can help you Roquette as a technology partner and a trusted supplier, provides scientists and researchers with a collaboration platform to beter understand and formulate with our ingredients. Innovation Hub | Roquette Pharma Solutions

LYCAGEL® VS 720 hydroxypropyl pea starch. It offers excellent film-forming properties for the manufacture of veggie soft capsules in both pharmaceutical and nutraceutical applications.

PEARLITOL® 200 GT, the only Mannitol allowing to produce and to develop drugs faster, thanks to its tableting properties - enhancing patient compliance without compromising drugs stability.

PEARLITOL® 200 GT mannitol is a direct compression excipient, specially designed to avoid capping, improve flowability and tabletability. It is a granulated form of mannitol with exceptional physical and chemical stability. It offers high API compatibility and no hygroscopicity. It is also a non-cariogenic...

The new facility will focus on the research of excipients for oral dosage forms, drug delivery systems, nutraceutical APIs and innovative pharma ingredients

Discover the wide range of products by Roquette in Pharmaceuticals and Neutraceuticals

The ramping up of vaccine manufacturing demand amid the COVID-19 pandemic had an initial impact on cell and gene therapy production but the regenerative medicine sector has largely weathered the storm, according to senior industry figures in a recent panel discussion at the CPHI Festival of Pharma virtual event.